Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00002030-200202150-00031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlabelled: Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 CD4-binding site (CD4bs) occur infrequently in macaques and humans and have not been reproducibly elicited in any outbred animal model. To address this challenge, we first isolated RHA10, an infection-induced rhesus bNAb with 51% breadth. The cryo-EM structure of RHA10 with HIV-1 envelope (Env) resembled prototypic human CD4bs bNAbs with CDR-H3-dominated binding.
View Article and Find Full Text PDFHigh prevalence of hepatitis C virus infection among adolescents and young adults attending HIV and sexual health clinics.
Int J STD AIDS
December 2024
Department of Pediatrics, Division of Infectious Disease, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Background: The prevalence of hepatitis C virus (HCV) infection among Thai adults is 0.5%-1.0%.
View Article and Find Full Text PDFHIV-1 viral decay in blood and semen in antiretroviral-naïve adults initiating dolutegravir/lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide.
Int J Antimicrob Agents
January 2025
Beijing Youan Hospital, Capital Medical University, Beijing, China. Electronic address:
Background: Co-formulated dolutegravir and lamivudine (DTG/3TC) is recommended as the first-line antiretroviral therapy (ART); however, the data on the viral decay in seminal plasma (SP) and blood plasma (BP), as well as changes in inflammatory biomarkers in BP, remain limited among antiretroviral-naïve people with HIV (PWH) receiving DTG/3TC. A prospective observational cohort study was conducted to compare the impact of DTG/3TC vs. bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) on viral decay kinetics and changes in inflammatory biomarkers in antiretroviral-naïve PWH.
View Article and Find Full Text PDFFunctional variability of Nef in antagonizing SERINC5 during acute to chronic HIV-1 infection.
AIDS
November 2024
National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun 130012, China.
Article Synopsis
- The study examines how long-term evolution of the HIV-1 Nef protein affects its ability to counteract the host factor SERINC5, which plays a role in viral infectivity.
- Analysis involved comparing Nef isolates from different infection stages in 19 individuals with subtype B or C HIV-1, revealing that subtype B showed a decline in Nef's ability to inhibit SERINC5 over time, unlike subtype C.
- The findings suggest that specific mutations in Nef are linked to variations in its function against SERINC5 and highlight the limited influence of host T cell responses on these mutations, providing insights into HIV-1 pathogenesis.*
Background: Antiretroviral therapy (ART) has improved the clinical management of HIV-1 infection. However, little is known about how the latest ART recommendations affect the heterogeneity of HIV-1 reservoir size.
Methods: We used a complete statistical approach to outline parameters underlying diversity in HIV-1 reservoir size in a cohort of 892 people with HIV-1 (PWH) on suppressive ART for >3 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!